ESTIMABL2
No Radioiodine Ablation vs. Low-Activity Radioiodine in Low-Risk Thyroid Cancer
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 730 patients with low-risk differentiated thyroid carcinoma after thyroidectomy, no radioiodine ablation was non-inferior to 1.1 GBq radioiodine plus rhTSH for event-free survival at 3 yr.
N
730
Disegno
Open-label non-inferiority RCT, 3 yr
Esito
Composite of functional, structural or biologic abnormalities at 3 yr
Rilevanza
2
RisultatoEvent-free survival 95.6 % vs 95.9 % — non-inferiority demonstrated.
Leboulleux S, et al. N Engl J Med. 2022;386(10):923-932. 10.1056/NEJMoa2111953
Discussione e critica
Practice-changing for low-risk DTC: radioiodine can be omitted entirely after total thyroidectomy in carefully selected patients.